Patents by Inventor Fabio Borella

Fabio Borella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR ORAL ADMINISTRATION OF PENTOSAN POLYSULFATE IN FORM OF NANOPARTICLES WITH IMPROVED INTESTINAL ABSORPTION
    Publication number: 20210260214
    Abstract: The present invention relates to pharmaceutical composition for the oral delivery of Pentosan Polysulfate sodium (PPS). In particular, the invention discloses compositions of PPS in form of nanoparticles with a suitable polymer aimed to improve the PPS absorption in the small intestine and reduce or eliminate the side effects in the colon.
    Type: Application
    Filed: May 16, 2019
    Publication date: August 26, 2021
    Applicant: NEXTRARESEARCH S.R.L.
    Inventors: Adolfo Gasparetto, Fabio Borella, Viviana Mascilongo, Ruggero Bettini, Fabio Sonvico, Marta Cito
  • ANALOGUES OF CYSTEAMINE AS THERAPEUTIC AGENTS FOR CYSTIC FIBROSIS
    Publication number: 20200179312
    Abstract: The present invention concerns a method of treatment of cystic fibrosis in a patient in need thereof, the method comprising administering an effective amount of a compound of formula I Wherein R1, X. Y and Z are as defined in the description.
    Type: Application
    Filed: November 22, 2019
    Publication date: June 11, 2020
    Applicant: I.E.R.F.C. EUROPEAN INSTITUTE FOR CYSTIC FIBROSIS RESEARCH
    Inventors: Luigi Maiuri, Valeria Villella, Fabio Borella, Giorgio Cozza, Andrea Venerando
  • Combined therapy for cystic fibrosis
    Patent number: 9730922
    Abstract: There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ?F508-CFTR mutation, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: August 15, 2017
    Assignee: I.E.R.F.C. Europ. Inst. for Cystic. Fibrosis Res.
    Inventors: Luigi Maiuri, Valeria Raia, Fabio Borella, Guido Kroemer
  • COMBINED THERAPY FOR CYSTIC FIBROSIS
    Publication number: 20150328203
    Abstract: There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ?F508-CFTR mutation, and pharmaceutical compositions thereof.
    Type: Application
    Filed: August 4, 2015
    Publication date: November 19, 2015
    Inventors: Luigi MAIURI, Valeria RAIA, Fabio BORELLA, Guido KROEMER
  • Combined therapy for cystic fibrosis
    Patent number: 9132123
    Abstract: There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ?F508-CFTR mutation, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: September 15, 2015
    Assignee: I.E.R.F.C. European Institute For Cystic Fibrosis Research
    Inventors: Luigi Maiuri, Valeria Raia, Fabio Borella, Guido Kroemer
  • Slow release pharmaceutical composition containing a bile acid as an active ingredient
    Patent number: 5510114
    Abstract: A slow-release pharmaceutical composition containing a bile acid as active ingredient and comprising at least one bioadhesive substance and at least one high specific gravity substance, an aliquot thereof being enteric coated and the remainder being non-enteric coated.
    Type: Grant
    Filed: May 2, 1994
    Date of Patent: April 23, 1996
    Assignee: Instituto Biochimico Italiano Giovanni Lorenzini S.p.A.
    Inventors: Fabio Borella, Alberto Brandt, Fabio Carli